Research summary ·
Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review pooled studies of SGLT2 inhibitor drugs in polycystic kidney disease. The abstract says these people were left out of earlier key trials. The review included clinical studies with 451 people. It looked at kidney and heart outcomes. It also looked at safety. The review was registered with PROSPERO.
What they found
Kidney filtering declined less in the first year than before the drug. But compared with other treatments, no such gain was shown. No clear difference in total kidney volume change was shown. The studies did not find major safety concerns.
What it means for patients
The authors say the evidence cannot yet show a kidney benefit. They say this applies to people with this kidney disease. The abstract does not show proof of harm.
Why it is not certain yet
The studies had small sample sizes. Most were observational designs. They also differed in clinical and method details. Safety findings come from this limited evidence too. The abstract does not say how long people took the drugs. The abstract says the studies came from a mix of designs.
Source
Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis.
PubMed · PMID 42586506We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Polycystic kidney disease publications